Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 8 | 2016 | 49 | 1.510 |
Why?
|
| Hemarthrosis | 6 | 2016 | 22 | 1.260 |
Why?
|
| Joint Diseases | 5 | 2012 | 105 | 0.920 |
Why?
|
| Synovitis | 4 | 2011 | 21 | 0.460 |
Why?
|
| Factor VIII | 5 | 2016 | 32 | 0.460 |
Why?
|
| Blood Platelets | 2 | 2006 | 30 | 0.430 |
Why?
|
| Coagulants | 2 | 2016 | 11 | 0.420 |
Why?
|
| Anticoagulants | 3 | 2011 | 76 | 0.380 |
Why?
|
| Mice | 6 | 2016 | 1128 | 0.270 |
Why?
|
| Platelet Adhesiveness | 1 | 2006 | 2 | 0.250 |
Why?
|
| Gangliosides | 1 | 2006 | 6 | 0.250 |
Why?
|
| Neuroblastoma | 1 | 2006 | 17 | 0.250 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2005 | 4 | 0.250 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 31 | 0.240 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 38 | 0.240 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 41 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 162 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 32 | 0.220 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 79 | 0.210 |
Why?
|
| Animals | 6 | 2016 | 3025 | 0.210 |
Why?
|
| Contusions | 1 | 2001 | 2 | 0.180 |
Why?
|
| Factor IX | 2 | 2012 | 7 | 0.170 |
Why?
|
| Epilepsy | 1 | 2001 | 59 | 0.170 |
Why?
|
| Humans | 12 | 2016 | 22848 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 477 | 0.150 |
Why?
|
| Synovial Membrane | 3 | 2008 | 47 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2007 | 489 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2016 | 256 | 0.120 |
Why?
|
| Models, Molecular | 1 | 2011 | 60 | 0.090 |
Why?
|
| Phenotype | 1 | 2011 | 254 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 187 | 0.080 |
Why?
|
| Hemophilia B | 1 | 2008 | 11 | 0.080 |
Why?
|
| Synovectomy | 1 | 2007 | 5 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2008 | 111 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 75 | 0.070 |
Why?
|
| X-Ray Microtomography | 1 | 2008 | 73 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 90 | 0.070 |
Why?
|
| Factor VIIa | 1 | 2007 | 7 | 0.070 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2007 | 13 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 214 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 16 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2006 | 23 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Platelet Transfusion | 1 | 2005 | 6 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2005 | 24 | 0.060 |
Why?
|
| Collagen | 1 | 2006 | 78 | 0.060 |
Why?
|
| Child | 2 | 2007 | 990 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 47 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 26 | 0.060 |
Why?
|
| Stress, Mechanical | 1 | 2006 | 150 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 26 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2005 | 16 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 127 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 218 | 0.060 |
Why?
|
| Thrombosis | 1 | 2005 | 38 | 0.060 |
Why?
|
| Bacteremia | 1 | 2005 | 99 | 0.060 |
Why?
|
| Genes, myc | 1 | 2004 | 6 | 0.060 |
Why?
|
| Oncogenes | 1 | 2004 | 11 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2004 | 23 | 0.060 |
Why?
|
| Iron | 1 | 2004 | 14 | 0.060 |
Why?
|
| Cell Division | 1 | 2004 | 72 | 0.060 |
Why?
|
| RNA | 1 | 2004 | 35 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 46 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2004 | 41 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 29 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 107 | 0.060 |
Why?
|
| Infant | 1 | 2005 | 449 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2005 | 205 | 0.050 |
Why?
|
| Cartilage, Articular | 1 | 2008 | 389 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 368 | 0.050 |
Why?
|
| Platelet Count | 1 | 2001 | 13 | 0.040 |
Why?
|
| Ketosis | 1 | 2001 | 6 | 0.040 |
Why?
|
| Time Factors | 1 | 2004 | 1220 | 0.040 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 11 | 0.030 |
Why?
|
| Joints | 1 | 2016 | 62 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 14 | 0.030 |
Why?
|
| Male | 2 | 2007 | 12453 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 685 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 1994 | 337 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 12 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 24 | 0.020 |
Why?
|
| Dependovirus | 1 | 2008 | 35 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 51 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2008 | 73 | 0.020 |
Why?
|
| Injections, Intra-Articular | 1 | 2008 | 92 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2007 | 9 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 343 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2007 | 121 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 262 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 549 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2007 | 2960 | 0.010 |
Why?
|
| Adult | 2 | 2007 | 6584 | 0.010 |
Why?
|
| Arthroscopy | 1 | 2007 | 1042 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 37 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 119 | 0.010 |
Why?
|
| Cisplatin | 1 | 1994 | 50 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1994 | 210 | 0.010 |
Why?
|
| Middle Aged | 1 | 1994 | 7555 | 0.000 |
Why?
|
| Female | 1 | 1994 | 12677 | 0.000 |
Why?
|